Pacira BioSciences (NASDAQ:PCRX) Stock Rating Reaffirmed as “Neutral” by HC Wainwright

Pacira BioSciences (NASDAQ:PCRX)‘s stock had its “neutral” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $36.50 price target on the stock, down from their previous price target of $38.00. HC Wainwright’s target price would suggest a potential upside of 0.30% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Royal Bank Of Canada lifted their target price on shares of Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 5th. Needham & Company LLC cut Pacira BioSciences from a “buy” rating to a “hold” rating in a research report on Thursday. Leerink Partners assumed coverage on Pacira BioSciences in a research note on Wednesday, September 9th. They set a “market perform” rating and a $28.00 target price on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $36.00 target price on shares of Pacira BioSciences in a report on Thursday. Finally, Truist Financial upped their price target on Pacira BioSciences from $30.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Pacira BioSciences presently has an average rating of “Hold” and a consensus price target of $31.44.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $36.39 on Friday. The company has a quick ratio of 3.94, a current ratio of 5.04 and a debt-to-equity ratio of 0.54. The stock has a market cap of $1.45 billion, a P/E ratio of 103.97 and a beta of 0.25. The business’s 50 day moving average price is $25.37 and its 200-day moving average price is $24.51. Pacira BioSciences has a 52 week low of $18.80 and a 52 week high of $36.46.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.08. The company had revenue of $192.40 million during the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.74 EPS. Equities research analysts anticipate that Pacira BioSciences will post 1.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the transaction, the insider owned 216,384 shares in the company, valued at $5,026,600.32. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Pacira BioSciences

Large investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new position in shares of Pacira BioSciences during the 2nd quarter valued at $51,000. Meeder Asset Management Inc. bought a new stake in shares of Pacira BioSciences in the first quarter worth $46,000. State of Wyoming purchased a new stake in Pacira BioSciences during the second quarter valued at $78,000. PNC Financial Services Group Inc. lifted its holdings in Pacira BioSciences by 15.1% in the first quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock valued at $85,000 after acquiring an additional 492 shares during the period. Finally, Keating Financial Advisory Services Inc. bought a new position in Pacira BioSciences in the second quarter valued at about $110,000. Institutional investors own 99.73% of the company’s stock.

Trending Headlines about Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris acquisition: Viatris will acquire Pacira’s marketed non-opioid pain products, including EXPAREL and ZILRETTA. The deal is expected to close by the end of 2026, subject to customary conditions, and Viatris expects it to be immediately accretive to its financial guidance metrics. Viatris Agrees to Acquire Pacira BioSciences
• Positive Sentiment: Analyst support: Pacira received an analyst upgrade, helping reinforce momentum following the takeover announcement. JPMorgan also raised its rating from “underweight” to “neutral” and set a $36.50 price target, broadly aligning with the proposed cash consideration. Pacira Stock Jumps on Analyst Upgrade
• Neutral Sentiment: Truist increased its price target to $31 while maintaining a “buy” rating, but the target is below the $36.50 acquisition price and is therefore less relevant if the deal closes. Jefferies and Needham reiterated “hold” ratings. Pacira Price Target Increase
• Negative Sentiment: Several shareholder law firms announced investigations into whether Pacira’s board obtained sufficient value for shareholders and conducted an adequate sale process. These reviews could create litigation or deal-execution risk, although no specific wrongdoing has been established. Shareholder Investigation

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.